Expression Of Lmo2 In Prostate Carcinoma And Adjacent Prostatic Parenchyma

LMO2 (LIM domain only) is a member of transcription factor family of proteins characterized by their cysteine-rich, zinc-binding LIM domains. Its expression in prostate cancer cells, as well as in adjacent stroma, is described in a study in a cohort of 83 patients treated with radical prostatectomy for clinically localized prostate adenocarcinoma. Authors found that LMO2 overexpression in prostate cancer was strongly associated with features indicative of worse prognosis (higher preoperative PSA, higher Gleason score, positive surgical margins, and extraprostatic extension of disease). Expression of LMO2 was also associated with biochemical disease progression. We analysed immunohistochemical expression of LMO2 in prostate cancer epithelial and stromal cells, as well as in adjacent parenchyma. Significant negative correlation between glandular expression of LMO2 in carcinoma and stromal expression in BPH (p = -0.238, P = 0.033) was found, but also between stromal expression in carcinomas and glandular expression in BPH (p = -0.255, P = 0.021). Positive correlation was found between stromal expression in BPH and stromal expression in carcinomas (p = 0.306, P = 0.005). Study results support the potential role of LMO2 in prostatic carcinogenesis and cancer progression.